Ligands to the integrin receptor α_vβ₃

Bibliography

• ALBELDA SM, BUCK CA: Intergins and other cell adhesion molecules. FASEB J. (1990) 4:2868–2880.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: versatility, modulation and signaling in cell adhesion. Cell (1992) 69:11–25.
   PubMed Web of Science ®Google Scholar
• COX D: Targets in integrin research. DNP (1995) 8:197–205.
   Google Scholar
• LEE J-0, RIEU P, ARNAOUT MA, LIDDINGTON R: Crystal structure of the a domain from the a subunit of integrin CR3 (CD11b/CD18). Cell (1995) 80:631–638.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E: RGD and other recognition sequences for integrins. Ann. Rev. Cell Dev. Biol. (1996) 12:697–715.
   PubMed Web of Science ®Google Scholar
• HUGHES PE, PFAFF M: 1ntegrin affinity modulation. Trends Cell Biol. (1998) 8:359–364.
   PubMed Web of Science ®Google Scholar
• MANIOTIS AJ, CHEN CS, INGBER DE: Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stablize structure. Proc. Natl. Acad. Sci. USA (1997) 94:849–854.
   PubMed Web of Science ®Google Scholar
• FITZGERALD LA, PONCZ M, STEINER B et al.: Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor a-subunits and platelet glycoprotein lib. Biochemistry (1987) 26:8158–8165.
   PubMed Web of Science ®Google Scholar
• JENNINGS LK, PHILLIPS DR: Purification of glycopro-teins lib and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein lib-ill complex." Biol. Chem. (1982) 257:10458–10466.
   PubMed Web of Science ®Google Scholar
• BODARY SC, NAPIER MA, MCLEAN JVV: Expression of recombinant platelet glycoprotein IlbIlla results in a functional fibrinogen-binding complex. J. Biol. Chem. (1989) 264:18859–18862.
   PubMedGoogle Scholar
• O'TOOLE TE, LOFTUS JC, PLOW EF et al.: Efficient surface expression of platelet GP lib-IIIa requires both subunits. Blood (1989) 74:14–18.
   Google Scholar
• SHATTIL SJ, KASHIWAGI H, PAMPORI N: Integrin signaling: the platelet paradigm. Blood (1998) 91:2645–2657.
   PubMed Web of Science ®Google Scholar
• FITZGERALD DJ, ROY L, CATELLA F, FITZGERALD GA: Platelet activation in unstable coronary disease. N Engl. J. Med. (1986) 315:983–989.
   PubMed Web of Science ®Google Scholar
• COOK NS, KOTTIRSCH G, ZERWES H-G: Platelet glycoprotein IIb/Illa antagonists. Drugs Fut. (1994) 19:135–159.
   Google Scholar
• SAMANEN J: GPIIb /IIIa antagonists. In: Annual Reports In Medicinal Chemistry. Bristol JA (Ed.), Academic Press, New York (1996):91–100.
   Google Scholar
• DUGGAN ME, NAYLOR-OLSEN AM, PERKINS JJ et al.: Non-peptide fibrinogen receptor antagonist. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J. Med. Chem. (1995) 38:3332–3341.
   Google Scholar
• ZABLOCKI JA, MIYANO M, GARLAND RB et al.: Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. a proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP lib-IIIa receptor. J. Med. Chem. (1993) 36:1811–1819.
   Google Scholar
• RAMASWAMY H, HEMLER ME: Cloning, primary structure and properties of a novel human integrin beta subunit. EMBO J. (1990) 9:1561–1568.
   PubMed Web of Science ®Google Scholar
• HUANG X, GRIFFITHS M, WU J, FARESE RV, SHEPPARD D: Normal development, wound healing, and adenovirus susceptibility in I35-deficient mice. Mol. Cell Biol. (2000) 20:755–759.
   PubMed Web of Science ®Google Scholar
• FELDING-HABERMANN B, CHERESH DA: Vitronectin and its receptors. Curr. Opin. Cell Biol. (1993) 5:864–868.
   PubMed Web of Science ®Google Scholar
• HARTMAN GD, DUGGAN ME: av133 integrin antagonists as inhibitors of bone resorption. Exp. Opin. Invest. Drugs (2000) 9(6):1281–1291.
   PubMed Web of Science ®Google Scholar
• SMITH JW, CHERESH DA: In tegrin (avI33)-ligand interaction. J. Biol. Chem. (1990) 265:2168–2172.
   PubMed Web of Science ®Google Scholar
• EASTELL R: Treatment of postmenopausal osteopo-rosis. N Engl. J. Med. (1998) 338:736–746.
   PubMed Web of Science ®Google Scholar
• KANIS JA, DELMAS P, COOPER C, TORGERSON D: for diagnosis and management of osteopo-rosis. Osteoporos. Int. (1997) 7:390–406.
   PubMed Web of Science ®Google Scholar
• PARFITT AM: Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. j Cell. Biol. (1994) 55:273–286.
   Google Scholar
• NESBITT S, NESBITT A: Biochemical characterization ofhuman osteoclast integrins. osteoclasts express av133, az pi and av131 integrins. J. Biol. Chem. (1993) 268:16737–16745.
   Google Scholar
• HORTON MA, TAYLOR ML, ARNETT TR, HELFRICH MH:-Gly -Asp (RGD) pep tides and the anti-vitronectin receptor antibody 23C6 inhibit cell spreading and dentine resorption by osteoclasts. Exp. Cell Res. (1991) 135:368–375.
   Google Scholar
• CHAMBERS TJ, FULLER K, DARBY JA, PRINGLE JA, HORTON MA: Monoclonal antibodies against osteoclasts inhibit bone resorption in vitro. Bone Miner. (1986) 1:127–135.
   PubMedGoogle Scholar
• YAMAMOTO M, FISHER JE, GENTILE M et al.: The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology (1998) 139:1411–1419.
   PubMedGoogle Scholar
• SATO M, SARDANA MK, GRASSER WA et al.: Echistatin is a potent inhibitor of bone resorption in culture. J Cell Biol. (1990) 111:1713–1723.
   PubMed Web of Science ®Google Scholar
• LEU C-T, WESOLOWSKI G, NAGY R et al.: Osteoclasts have over 107 high affinity echistatin binding sites (RGD-integrtins). j Bone Min. (1997) 12:S416.
   Google Scholar
• ENGLEMAN VW, NICKOLS GA, ROSS FP et al.: A peptidomimetic antagonist of the av133 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. (1997) 99:2284–2292.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP G, COUSINS RD etal.: An orally active av133 antagonist prevents bone loss in the ovariecto-mized rat model. Bone (1998) 22:28S.
   Google Scholar
• ELICEIRI BP, CHERESH DA: The role of av integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin. Invest. (1999) 103:1227–1230.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, CLARK RAF, CHERESH DA: Requirement of vascular integrin av133 for angiogenesis. Science (1994) 2 64:569–571.
   Google Scholar
• BROOKS PC, MONTGOMERY AMP, ROSENFELD M et al.: Integrin avi33 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79:1157–1164.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, STROMBLAD S, KLEMKE R et al.: Antiin-tegrin av133 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96:1815–1822.
   PubMed Web of Science ®Google Scholar
• CARRON CP, MEYER DM, PEGG JA et al.: A p eptidomi-metic antagonist of the integrin av133 inhibits Izydig cell tumor growth and the development of hypercal-cemia of malignancy. Cancer Res. (1998) 58:1930–1935.
   PubMed Web of Science ®Google Scholar
• FRIEDLANDER M, BROOKS PC, SHAFFER RW et al.: Defini-tion of two angiogenic pathways by distinct av integrins. Science (1995) 270:1500–1502.
   PubMed Web of Science ®Google Scholar
• LUNA J, TOBE T, MOUSA SA, REILLY TM, CAMPOCHIAROPA: Antagonists of integrin av133 inhibit retinal neovascularization in a murine model. Lab. Inv. (1996) 75:563–573.
   PubMed Web of Science ®Google Scholar
• STORGARD CM, STUPACK DG, JONCZYK A et al.: angiogenesis and arthritic disease in rabbits treated with an av133 antagonist. j Clin. Invest. (1999) 103:47–54.
   PubMed Web of Science ®Google Scholar
• HAUBNER R, FINSINGER D, KESSLER H: Stereoisomericpeptide libraries and peptidomimetics for designing selective inhibitors of the av133 integrin for a new cancer therapy. Angew. Chem. (1997) 36:1374–1389.
   Google Scholar
• PEYMAN A, WEHNER V, KNOLLE J et al.: RGD mimeticscontaining a central hydantoin scaffold: av133 vs. a11b133 selectivity requirements. Bioorg. Med. Chem. Lett. (2000) 10:179–182.
   Google Scholar
• BATT DG, PETRAITIS JJ, HOUGHTON GC et al.: Disubsti-tuted indazoles as potent antagonists of the integrin OC33. J. Med. Chem. (2000) 43:41–58.
   PubMed Web of Science ®Google Scholar
• KEENAN RM, MILLER WH, BARTON LS et al.: Orally bioavailable nonpeptide vitronectin receptor antago-nists containing 2-aminopyridine arginine mimetics.. Med. Chem. Lett. (1999) 9:1801–1806.
   Google Scholar
• MILLER WH, BONDINELL WE, COUSINS RD et al.: Orally bioavailable nonpeptide vitronectin receptor antago-nists with efficacy in an osteoporosis model. Bioorg. Med. Chem. Lett. (1999) 9:1807–1812.
   PubMed Web of Science ®Google Scholar
• LARK MW, STROUP GB, HVVANG SM et al.: Design and characterization of orally active Arg-Gly-Asp pep tidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J Pharm. Exp. (1999) 291:612–617.
   PubMed Web of Science ®Google Scholar
• WARD KW, AZZARANO LM, BONDINELL WE et al.: and interspecies scaling of a novel vitronectin receptor antagonist. Drug Meta.. (1999) 27:1232–1241.
   PubMed Web of Science ®Google Scholar
• PERRIN DD: Dissociation Constants Of Organic Bases. In: Aqueous Solution (1965).
   Google Scholar
• DUGGAN ME, DUONG LT, FISHER JE et al: Non-peptide av133 antagonists. I. transformation of a potent, integrin selective allb133 antagonist into the potent av133 antagonist L-767,635. J Med. Chem. (2000): (Accepted).
   Google Scholar
• ADANG AEP, LUCAS H, DE MAN APA, ENGH RA, GROOTENHUIS PDJ: Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety. Bioorg. Med. Chem. Lett. (1998) 8:3603–3608.
   PubMed Web of Science ®Google Scholar
• YATES AJ, RODAN GA: Alendronate and osteoporosis.DDT (1998) 3:69–78.
   Web of Science ®Google Scholar
• EVANS G, BRYANT HU, MAGEE D, SATO M, TURNER RT: effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology (19 9 4) 134:2283-2288.
   Google Scholar
• MCHUGH KP, HODIVALA-DILKE K, ZHENG M-H et al: lacking 133 integrins are osteoclerotic because of dysfunctional osteoclasts. J. Clin. Invest. (2000) 1 0 5 :433–440.
   Google Scholar